Sun Pharma & ICGEB sign exclusive deal on dengue vaccine — ARTES adds experience in VLP development and production
NEW DELHI, India I October 19, 2016
International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma today announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause disease in humans. ICGEB has developed a tailored recombinant virus-like-particle (VLP) based tetravalent dengue vaccine, containing host-receptor binding domain of envelope protein of all the four DENV serotypes. ICGEB has conducted pre-clinical studies over the past seven years and developed the existing Know-How and Patents for this dengue vaccine candidate.
Sun Pharma invests over US$ 300 million annually on research and development in pharmaceuticals and biologics. The Company will use its in-house expertise as well as expertise of its Associate company, ARTES Biotechnology GmbH, in development of dengue vaccine. ARTES will add their experience and proprietary know-how in production of VLP based vaccines from yeast production cell lines. Hep‑B and HPV vaccines developed by ARTES are licensed to several companies worldwide and a Malaria vaccine program is sponsored by PATH (Malaria Vaccine Initiative). Taken together, the Company has past experience in development of Hep‑B and Typhoid vaccines, as well as complex vaccines, such as HPV and Malaria.
For the full text, see: http://www.sunpharma.com/media/press-releases